TRELAGLIPTIN SUCCINATE

Possibly Marketed Outside US

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C18H20FN5O2.C4H6O4
Molecular Weight	475.4701
Optical Activity	UNSPECIFIED
Defined Stereocenters	1 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

OC(=O)CCC(O)=O.CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC3=CC(F)=CC=C3C#N)C1=O

InChI

InChIKey=OGCNTTUPLQTBJI-XFULWGLBSA-N

InChI=1S/C18H20FN5O2.C4H6O4/c1-22-17(25)8-16(23-6-2-3-15(21)11-23)24(18(22)26)10-13-7-14(19)5-4-12(13)9-20;5-3(6)1-2-4(7)8/h4-5,7-8,15H,2-3,6,10-11,21H2,1H3;1-2H2,(H,5,6)(H,7,8)/t15-;/m1./s1

HIDE SMILES / InChI

Molecular Formula	C4H6O4
Molecular Weight	118.088
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	C18H20FN5O2
Molecular Weight	357.3821
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	1 / 1
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/27181699
Curator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/24622716 | https://www.ncbi.nlm.nih.gov/pubmed/21186796 | https://www.takeda.com/news/2015/20150528_6997.html

Trelagliptin (SYR-472), a novel dipeptidyl peptidase-4 inhibitor used for the treatment of type 2 diabetes mellitus. Trelagliptin (as the salt Trelagliptin succinate) was approved for use in Japan in March 2015. Takeda, the company that developed Trelagliptin, chose to not get approval for the drug in the USA and EU.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Dipeptidyl peptidase 4 8 Target ID: P27487 Gene ID: 1803.0 Gene Symbol: DPP4 Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/24622716	Inhibitor 8297		4.0 nM [IC50]
Dipeptidyl peptidase IV 37 Target ID: CHEMBL284 Sources: https://www.ncbi.nlm.nih.gov/pubmed/21186796	Inhibitor 8297		4.0 nM [IC50]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Type 2 diabetes mellitus 259 Sources: https://clinicaltrials.gov/ct2/show/NCT03014479	Primary		Approved 8429	Zafatek Approved Use Unknown Launch Date 2015

PubMed

Title	Date	PubMed
Trelagliptin (SYR-472, Zafatek), Novel Once-Weekly Treatment for Type 2 Diabetes, Inhibits Dipeptidyl Peptidase-4 (DPP-4) via a Non-Covalent Mechanism.	2016	27328054

Patents

Sample Use Guides

In Vivo Use Guide

Usually, for adults, 100 mg of trelagliptin is orally administered once a week

Route of Administration: Oral

In Vitro Use Guide

Trelagliptin (1 M) were incubated 0, 5, 15, 30 minute at 37 °C in phosphate buffer (50 mM, pH 7.4) containing rat or human liver microsomes (1 mg/mL protein) and NADPH (4 mM). Metabolic stability of Trelagliptin was assayed by LC/MS

Substance Class	Chemical Created by `admin` on `Sat Dec 16 01:30:42 GMT 2023` Edited by `admin` on `Sat Dec 16 01:30:42 GMT 2023`
Record UNII	4118932Z90
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

TRELAGLIPTIN SUCCINATE

Official Name

English

SYR-111472 SUCCINATE

Code

English

BUTANEDIOIC ACID, COMPD. WITH 2-((6-((3R)-3-AMINO-1-PIPERIDINYL)-3,4-DIHYDRO-3-METHYL-2,4-DIOXO-1(2H)-PYRIMIDINYL)METHYL)-4-FLUOROBENZONITRILE (1:1)

Common Name

English

SYR111472 SUCCINATE

Code

English

SYR-472

Code

English

TRELAGLIPTIN SUCCINATE [USAN]

Common Name

English

TRELAGLIPTIN SUCCINATE [JAN]

Common Name

English

Trelagliptin succinate [WHO-DD]

Common Name

English

ZAFATEK

Brand Name

English

TRELAGLIPTIN SUCCINATE [MI]

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C98086